Author: Peter Göttel

We published a new peer-reviewed paper: "Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins". Get the full text here.

Durchbruch in der Entwicklung eines schnell verfügbaren, effektiven Wirkstoffs gegen das Coronavirus Aptamer BC 007 von Berlin Cures ist auf dem Weg in klinische Phase-II/III-Studie Berlin (pts008/06.07.2020/10:00) - Forscher des Life-Science-Unternehmens Berlin Cures haben kürzlich in Tests nachgewiesen, dass das von ihnen entwickelte Aptamer BC 007 in der Lage ist, das pandemische Co...

Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19 Phase II/III clinical trial is scheduled to start in the second half of 2020 Berlin, Germany – 24 June 2020 – Berlin Cures Holding AG, a biotech company developing aptamers for autoimmune diseases, today announces that it is evaluating BC 007, a β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDN...

Read full text here: https://www.teknoscienze.com/berlin-cures-announces-start-of-phase-iia-for-its-dna-based-neutralizer-of-β1-adrenoceptor-autoantibodies/

ZUG, Switzerland, Dec. 6, 2018 /PRNewswire/ -- Swiss drug developer Berlin Cures Holding AG today announced the establishment of a steering committee of renowned cardiologists focused on ensuring expert input during the design and implementation of the Phase 2 study of BC 007 for the treatment of dilated cardiomyopathy. "By convening an international team of experts to provide guidance around t...

  https://www.sciencedirect.com/science/article/pii/S0022354918302053  

ZUG, Switzerland, Aug. 22, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the successful completion of its Phase 1 study of BC 007, a DNA-based aptamer compound that binds to and eliminates functional pathogenic autoantibodies for the treatment of cardiomyopathy. "The safety profile of BC 007 continues to be excellent," said Dr. Johannes Müller, founder and president of the Bo...